vs
Side-by-side financial comparison of PLAYSTUDIOS, Inc. (MYPS) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $55.4M, roughly 1.1× PLAYSTUDIOS, Inc.). PLAYSTUDIOS, Inc. runs the higher net margin — -24.7% vs -92.6%, a 67.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -18.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -15.6%).
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MYPS vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $55.4M | $60.1M |
| Net Profit | $-13.7M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | -17.7% | -87.1% |
| Net Margin | -24.7% | -92.6% |
| Revenue YoY | -18.3% | 83.8% |
| Net Profit YoY | 38.9% | — |
| EPS (diluted) | $-0.12 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $55.4M | $57.3M | ||
| Q3 25 | $57.6M | $51.3M | ||
| Q2 25 | $59.3M | $48.5M | ||
| Q1 25 | $62.7M | $32.7M | ||
| Q4 24 | $67.8M | $41.8M | ||
| Q3 24 | $71.2M | $33.3M | ||
| Q2 24 | $72.6M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $-13.7M | $-47.5M | ||
| Q3 25 | $-9.1M | $-52.9M | ||
| Q2 25 | $-2.9M | $-46.6M | ||
| Q1 25 | $-2.9M | $-49.5M | ||
| Q4 24 | $-22.4M | $-43.3M | ||
| Q3 24 | $-3.1M | $-43.6M | ||
| Q2 24 | $-2.6M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | -17.7% | -82.2% | ||
| Q3 25 | -13.6% | -102.6% | ||
| Q2 25 | -5.9% | -93.4% | ||
| Q1 25 | -4.4% | -143.7% | ||
| Q4 24 | -33.1% | -98.6% | ||
| Q3 24 | -6.7% | -132.0% | ||
| Q2 24 | -5.5% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | -24.7% | -83.0% | ||
| Q3 25 | -15.8% | -103.1% | ||
| Q2 25 | -5.0% | -96.1% | ||
| Q1 25 | -4.6% | -151.4% | ||
| Q4 24 | -33.1% | -103.6% | ||
| Q3 24 | -4.3% | -131.2% | ||
| Q2 24 | -3.6% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $-0.12 | $-0.73 | ||
| Q3 25 | $-0.07 | $-0.82 | ||
| Q2 25 | $-0.02 | $-0.75 | ||
| Q1 25 | $-0.02 | $-0.81 | ||
| Q4 24 | $-0.18 | $-0.71 | ||
| Q3 24 | $-0.02 | $-0.73 | ||
| Q2 24 | $-0.02 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.9M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $227.9M | $122.9M |
| Total Assets | $290.6M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $104.9M | $388.9M | ||
| Q3 25 | $106.3M | $416.1M | ||
| Q2 25 | $112.9M | $291.0M | ||
| Q1 25 | $107.1M | $314.5M | ||
| Q4 24 | $109.2M | $320.6M | ||
| Q3 24 | $105.2M | $298.4M | ||
| Q2 24 | $106.3M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $227.9M | $139.1M | ||
| Q3 25 | $238.9M | $148.8M | ||
| Q2 25 | $245.3M | $-11.9M | ||
| Q1 25 | $244.1M | $18.9M | ||
| Q4 24 | $244.7M | $21.7M | ||
| Q3 24 | $265.2M | $11.2M | ||
| Q2 24 | $263.6M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $290.6M | $480.2M | ||
| Q3 25 | $299.2M | $506.9M | ||
| Q2 25 | $316.2M | $372.7M | ||
| Q1 25 | $313.8M | $386.7M | ||
| Q4 24 | $323.0M | $392.3M | ||
| Q3 24 | $330.6M | $363.6M | ||
| Q2 24 | $333.4M | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | — |
| Free Cash FlowOCF − Capex | $3.6M | — |
| FCF MarginFCF / Revenue | 6.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.7M | $-25.4M | ||
| Q3 25 | $5.7M | $-26.6M | ||
| Q2 25 | $13.6M | $-23.3M | ||
| Q1 25 | $3.3M | $-40.4M | ||
| Q4 24 | $11.6M | $-18.8M | ||
| Q3 24 | $14.6M | $-25.2M | ||
| Q2 24 | $14.5M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $3.6M | — | ||
| Q3 25 | $5.4M | — | ||
| Q2 25 | $13.2M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $11.5M | — | ||
| Q3 24 | $13.9M | — | ||
| Q2 24 | $12.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.5% | — | ||
| Q3 25 | 9.3% | — | ||
| Q2 25 | 22.3% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 17.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 2.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
